TIME for a successful cancer vaccine in NSCLC?

Lancet Oncol. 2016 Feb;17(2):131-132. doi: 10.1016/S1470-2045(15)00554-9. Epub 2015 Dec 23.

Authors

Charles A Butts¹, Randeep Sangha²

Affiliations

¹ Department of Oncology, University of Alberta, Edmonton, AB TRG 2R3, Canada; Cross Cancer Institute, Edmonton, AB, Canada. Electronic address: charles.butts@albertahealthservices.ca.
² Department of Oncology, University of Alberta, Edmonton, AB TRG 2R3, Canada; Cross Cancer Institute, Edmonton, AB, Canada.

PMID: 26727164
DOI: 10.1016/S1470-2045(15)00554-9

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cancer Vaccines / therapeutic use*
Carcinoma, Non-Small-Cell Lung / therapy*
Female
Humans
Lung Neoplasms / therapy*
Lymphocytes / chemistry*
Male
Membrane Glycoproteins / therapeutic use*

Substances

Cancer Vaccines
Membrane Glycoproteins